/ATAI
ATAI Stock - Atai Beckley N.V
Healthcare|Medical - PharmaceuticalsNASDAQ
$3.62-3.72%
$0.14 (-3.72%) • Jan 13
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.55
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+286.7%upside
Target: $14.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATAI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.58 – $3.66
TARGET (TP)$14.00
STOP LOSS$3.33
RISK/REWARD1:35.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.62
52W High$6.75
52W Low$1.15
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $308,000 | $314,000 | $233,000 | $20.38M | N/A |
| Gross Profit | $308,000 | $314,000 | $233,000 | $20.38M | N/A |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-102,691,000 | $-125,471,000 | $-144,787,000 | $-135,805,000 | $-104,162,000 |
| Net Income | $-149,269,000 | $-40,224,000 | $-152,385,000 | $-167,808,000 | $-169,843,000 |
| Net Margin | -48464.0% | -12810.2% | -65401.3% | -823.6% | N/A |
| EPS | $-0.93 | $-0.25 | $-0.91 | $-0.83 | $-0.67 |
Company Overview
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$12
Average Target
↑ 231.5% Upside
Now
$6
Low
$12
Average
$18
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 13th 2025 | Needham | Initiation | Buy | $12 |
| July 29th 2025 | Oppenheimer | Initiation | Outperform | $14 |
| November 18th 2024 | H.C. Wainwright | Reiterated | Buy | $10← $15 |
| April 3rd 2024 | Maxim Group | Upgrade | Buy | $6 |
| November 1st 2022 | Loop Capital | Initiation | Buy | $18 |
Earnings History & Surprises
ATAIBeat Rate
44%
Last 18 quarters
Avg Surprise
-30.5%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$-0.28
Q4 2025
EPS Surprise History
Q1 24
+29.4%
$-0.12vs$-0.17
Q2 24
+15.0%
$-0.17vs$-0.20
Q3 24
-111.8%
$-0.36vs$-0.17
Q4 24
-6.7%
$-0.16vs$-0.15
Q1 25
-71.4%
$-0.24vs$-0.14
Q2 25
+21.1%
$-0.15vs$-0.19
Q3 25
-16.7%
$-0.14vs$-0.12
Q4 25
-133.3%
$-0.28vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | $-0.12 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.12 | $-0.28 | -133.3% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q1 2025 | Mar 17, 2025 | $-0.14 | $-0.24 | -71.4% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.15 | $-0.16 | -6.7% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.17 | $-0.36 | -111.8% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.20 | $-0.17 | +15.0% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.20 | $-0.14 | +30.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.21 | $-0.21 | 0.0% | = MET |
Q2 2023 | May 11, 2023 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q1 2023 | Mar 24, 2023 | $-0.23 | $-0.28 | -21.7% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-0.23 | $-0.63 | -173.9% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.28 | $-0.21 | +25.0% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.13 | $-0.31 | -138.5% | ✗ MISS |
Latest News
AtaiBeckley Highlights 2026 Outlook With Advancing Clinical Programs And Financial Resources Supporting Operations Into 2029
📈 PositiveBenzinga•Jan 8, 2026, 12:14 PM
Atai Life Sciences shares are trading higher after Jones Trading initiated coverage on Atai Beckley with a Buy rating and a $16 price target.
📈 PositiveBenzinga•Dec 23, 2025, 03:41 PM
Jones Trading Initiates Coverage On Atai Beckley with Buy Rating, Announces Price Target of $16
📈 PositiveBenzinga•Dec 23, 2025, 01:59 PM
Atai Beckley Granted New Patent Covering EMP-01, Further Strengthening IP Estate And Long-Term Exclusivity For The Program
📈 PositiveBenzinga•Dec 11, 2025, 12:04 PM
ATAI Life Sciences Q3 EPS $(0.28) Misses $(0.12) Estimate, Sales $749.000K Beat $55.560K Estimate
➖ NeutralBenzinga•Nov 12, 2025, 12:14 PM
Atai Beckley Announces Topline Data From Phase 2b Open-Label Extension Study Of BPL-003, Showing 12 mg Dose Administered Eight Weeks After 0.3 mg, 8 mg Or 12 mg Dose Provided Additional Clinically Meaningful Effects And Was Generally Well Tolerated
📈 PositiveBenzinga•Nov 10, 2025, 12:12 PM
Canaccord Genuity Maintains Buy on ATAI Life Sciences, Raises Price Target to $14
📈 PositiveBenzinga•Oct 22, 2025, 01:50 PM•Also:
Reported Earlier, atai Life Sciences Prices $130M Public Offering Of 23.725M Common Shares At $5.48 Per Share To Advance Clinical Pipeline
➖ NeutralBenzinga•Oct 17, 2025, 05:52 AM
ATAI stock has given up its prior gain. atai Life Sciences shares were trading higher after the company announced that the FDA granted Breakthrough Therapy designation to BPL-003 nasal spray for adult patients with treatment-resistant depression.
➖ NeutralBenzinga•Oct 16, 2025, 08:54 PM
atai Life Sciences shares are trading higher after the company announced that the FDA granted Breakthrough Therapy designation to BPL-003 nasal spray for adult patients with treatment-resistant depression.
📈 PositiveBenzinga•Oct 16, 2025, 08:23 PM
atai Life Sciences Announces Proposed Public Offering; Terms Not Disclosed
➖ NeutralBenzinga•Oct 16, 2025, 08:13 PM
atai Life Sciences And Beckley Psytech Announces That FDA Has Granted Breakthrough Therapy Designation To Their BPL-003 Nasal Spray For Adults With Treatment-Resistant Depression
📈 PositiveBenzinga•Oct 16, 2025, 08:13 PM
Psychedelic stocks gain after positive remarks from GOP Senator in North Carolina
📈 PositiveSeeking Alpha•Oct 14, 2025, 06:06 PM•Also: , ,
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
📈 PositiveBenzinga•Oct 13, 2025, 05:28 PM•Also: , ,
Needham Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $12
📈 PositiveBenzinga•Oct 13, 2025, 10:08 AM
'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
➖ NeutralBenzinga•Oct 2, 2025, 03:03 PM•Also: , ,
ATAI Life Sciences N.V. Says Certain Selling Securityholders May Offer And Sell Common Shares, Including Up To 45.3M Shares By Selling Securityholders
➖ NeutralBenzinga•Sep 29, 2025, 09:40 PM•Also:
Atai Life Sciences N.V. Files For Potential Mixed Shelf; Size Not Disclosed
➖ NeutralBenzinga•Sep 29, 2025, 09:33 PM
atai Life Sciences rises after promising data from depression trial
📈 PositiveSeeking Alpha•Sep 23, 2025, 03:33 PM
HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
📈 PositiveBenzinga•Sep 23, 2025, 02:56 PM
Frequently Asked Questions about ATAI
What is ATAI's current stock price?
Atai Beckley N.V (ATAI) is currently trading at $3.62 per share. The stock has moved -3.72% today.
What is the analyst price target for ATAI?
The average analyst price target for ATAI is $14.00, based on 1 analyst.
What sector is Atai Beckley N.V in?
Atai Beckley N.V operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the NASDAQ exchange.
What is ATAI's market cap?
Atai Beckley N.V has a market capitalization of $0.68 billion, making it a small-cap company.
Does ATAI pay dividends?
No, Atai Beckley N.V does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.53
Mkt Cap: $1.0B
DNTH
Dianthus Therapeutics, Inc.
$43.33
Mkt Cap: $1.6B
ELVN
Enliven Therapeutics, Inc.
$25.57
Mkt Cap: $1.5B
IMTX
Immatics N.V.
$9.33
Mkt Cap: $1.1B
INBX
Inhibrx Biosciences, Inc.
$73.15
Mkt Cap: $1.1B
NKTR
Nektar Therapeutics
$36.24
Mkt Cap: $0.7B
ORIC
ORIC Pharmaceuticals, Inc.
$10.26
Mkt Cap: $1.0B
RLAY
Relay Therapeutics, Inc.
$7.96
Mkt Cap: $1.4B
SANA
Sana Biotechnology, Inc.
$4.70
Mkt Cap: $1.3B
SNDX
Syndax Pharmaceuticals, Inc.
$20.20
Mkt Cap: $1.7B
Explore stocks similar to ATAI for comparison